| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer Center
Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center Join the University of Vermont Cancer Center as Participating Clinical Sites
The PanTheR Study is Gathering Expanded Safety and Performance Data of the FDA-Cleared RenovoCath® Device and its Associated Survival Outcomes in Patients Diagnosed with Solid Tumors
MOUNTAIN VIEW, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, today announced that the first registry-eligible patient procedure in its PanTheR Post-Marketing Registry Study (NCT06805461) has been successfully completed at the University of Vermont Cancer Center.
RenovoRx also announced that Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center have joined the University of Vermont Cancer Center as participating clinical sites in the PanTheR registry study. The Principal Investigators at the first three PanTheR clinical sites include Dr. Ripal Gandhi, interventional radiologist at Baptist Health Miami Cancer Institute, Dr. Paula Novelli, interventional radiologist at University of Pittsburgh Medical Center, and Dr. Conor O'Neill, surgical oncologist at the University of Vermont Cancer Center. The study has commenced at the University of Vermont Cancer Center with Dr. O'Neill's team, with the additional two sites expected to initiate patient procedures soon.
These milestones underscore the important role of the PanTheR study in assessing the safety and effectiveness of RenovoCath in real-world settings. RenovoRx plans to issue additional updates as patient enrollment accelerates and cancer treatments delivered with RenovoCath expand across a broader range of solid tumors and participating sites.
Posted In: RNXT
